Saturday 17 October 2026
Export SCLX’s income statement to Excel — free account
Scilex Holding Company
SCLX Healthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024. In the quarter to June 2026, revenue fell 22.8%, EPS fell 124.4%, free cash flow fell 203.8% and total debt rose 102.7%, each against the same quarter a year earlier.
2.83
0.01
+0.35%
Follow SCLX
| Dec '17 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 4 | 4 | 6 | 3 |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | (8.05) | 340.70 | (3.80) | (11.80) | (13.45) | (7.96) |
P/S ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 11.69 | 3.54 | 1.65 | 2.77 |
Altman Z″-Score (non-manufacturers) |
— | — | (1,192.57) | (28.02) | (30.94) | (22.43) | (18.49) | (36.61) | (41.88) | (22.99) |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.83 | 22.96 |
Beneish M-Score |
— | — | — | — | (6.16) | — | (1.83) | (7.64) | (7.30) | (7.77) |
P/Operating CF |
— | — | (2,848,373.08) | (2,848,373.08) | (29.72) | (29.75) | (613.22) | (30.74) | 36.85 | (4.80) |
P/B ratio |
— | — | 198,015.24 | 198,015.24 | 0.00 | 0.00 | 12.27 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | 198,015.24 | 198,015.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 11.78 | 5.89 | 2.22 | 5.19 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 0.00 | 0.00 | (33.51) | (33.54) | (21.08) | (13.29) | 6.50 | 41.14 |
EV/FCF |
— | — | 0.00 | 0.00 | (33.51) | (33.54) | (21.07) | (13.27) | 6.51 | 42.97 |
Quick Ratio |
— | 0.17 | 0.17 | 0.11 | 0.11 | 0.52 | 0.52 | 0.15 | 0.11 | 0.05 |
Current Ratio |
— | 0.17 | 0.17 | 0.14 | 0.14 | 0.66 | 0.66 | 0.19 | 0.16 | 0.08 |
Net Debt/EBITDA |
— | (15.00) | 0.00 | (4.75) | (5.35) | 0.00 | 0.05 | (1.03) | (0.40) | (0.27) |
Debt/Assets |
0.00% | 62.66% | 0.00% | 198.57% | 171.29% | 0.00% | 0.00% | 107.03% | 37.52% | 22.81% |
Debt/Equity |
— | 6.68 | 0.00 | (0.69) | (0.60) | 0.00 | 0.00 | (0.63) | (0.18) | (0.39) |
Asset Turnover |
— | 0.00 | 118.10 | 0.00 | 0.80 | 0.00 | 0.46 | 0.50 | 0.58 | 0.13 |
Operating CF/Net income |
— | 0.21 | 0.66 | 0.32 | 0.32 | 0.91 | 0.91 | 0.12 | (0.27) | (0.01) |
Capex/Depreciation |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 |
Interest Coverage |
— | — | (2.69) | (65.50) | (3.05) | — | (5.27) | (98.72) | (42.48) | (30.20) |
| — | (33.69%) | (254,112.30%) | 0.00% | 79.00% | 0.00% | 24.90% | 244.29% | 39.83% | 199.06% | |
| — | (6.32%) | (23,819.05%) | 0.00% | (226.35%) | 0.00% | (28.41%) | (177.79%) | (74.96%) | (175.78%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (92.93%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 4.19% | 31,616.10% | 61.27% | 60.73% | 175.26% | 161.55% | 82.30% | 33.49% | 93.23% |
Average Days of Receivables |
— | — | 0.00 | 166.29 | 166.29 | 203.80 | 203.80 | 270.16 | 170.55 | 183.92 |
Research and Development Expense of Revenue |
— | — | 42.28% | 29.38% | 29.38% | 23.81% | 23.81% | 27.27% | 17.04% | 68.46% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 182.39% | 161.39% | 161.52% | 170.52% | 170.62% | 255.95% | 210.31% | 882.17% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.67 | 0.67 | 0.62 | 0.62 | 0.49 | 0.49 | 0.38 |
Share Based Compensation of Revenue |
— | — | 22.90% | 0.00% | 18.59% | 0.00% | 13.88% | 31.23% | 27.72% | 51.21% |
Graham Net Nets |
— | — | 0.00 | 0.00 | (0.34) | (0.33) | (0.05) | (1.37) | (2.61) | (6.42) |
Graham Number |
— | — | 0.00 | 0.00 | 175.64 | 42.27 | 0.00 | 217.02 | 56.07 | 125.46 |
Earnings Yield |
— | — | 0.00% | 0.00% | (10.64%) | (10.63%) | (5.26%) | (101.45%) | (78.63%) | (479.61%) |
Free Cash Flow Yield |
— | — | 0.00% | 0.00% | (3.45%) | (3.44%) | (4.78%) | (12.52%) | 20.69% | 4.36% |
Revenue per Share |
— | 0.00 | 6.20 | 0.24 | 8.24 | 0.28 | 9.91 | 12.54 | 5.62 | 2.74 |
Operating CF per Share |
— | 0.00 | (8.28) | (0.22) | (7.54) | (0.16) | (5.54) | (5.56) | 1.92 | 0.35 |
Capex per Share |
— | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) |
Free Cash Flow per Share |
— | 0.00 | (8.28) | (0.22) | (7.54) | (0.16) | (5.54) | (5.56) | 1.92 | 0.33 |
Cash per Share |
— | 0.00 | 0.01 | 0.03 | 1.14 | 0.02 | 0.57 | 1.05 | 0.33 | 1.00 |
Shareholders Equity per Share |
— | 0.00 | 0.00 | (1.69) | (58.92) | 0.27 | 9.44 | (46.41) | (19.15) | (19.19) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 0.00 | (1.69) | (58.92) | 0.27 | 9.44 | (46.41) | (19.15) | (19.19) |
Free Cash Flow |
— | 0.00 | (31.49) | (28.66) | (28.66) | (21.26) | (21.26) | (20.74) | 19.35 | 3.68 |
Working Capital |
— | (0.15) | (0.15) | (146.42) | (146.42) | (15.23) | (15.23) | (203.60) | (218.09) | (445.29) |
Capital Expenditures |
— | — | (0.02) | — | — | (2.07) | (0.01) | (0.03) | — | (0.13) |
Net Current Asset Value |
— | (0.15) | (0.15) | (278.80) | (278.80) | (20.68) | (20.68) | (227.47) | (244.05) | (538.37) |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | 0.00 | 1.97 | 14.52 | 2.34 | 9.20 | 5.83 | 6.16 | 5.76 |
Cash ROIC |
— | (0.75%) | (63,995.93%) | 44.24% | 33.31% | 0.00% | (55.34%) | 34.23% | (12.52%) | (3.13%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 2.19 | 0.00 | 2.14 | 1.67 | 1.85 | 1.45 |
Accounts Payable Turnover |
— | — | 18.01 | 0.00 | 0.30 | 0.00 | 0.67 | 0.63 | 0.36 | 0.15 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 1.42 | 0.00 | 5.48 | 5.61 | 5.02 | 2.93 |
Average Days of Payables |
— | — | 5.10 | 210.93 | 2,399.72 | 208.99 | 285.66 | 953.27 | 1,150.84 | 2,970.76 |
Days of Inventory on Hand |
— | — | 0.00 | 126.15 | 257.33 | 34.08 | 46.58 | 98.09 | 53.28 | 164.92 |
Average Receivables |
— | — | — | — | 14.27 | 17.75 | 17.75 | 27.92 | 30.52 | 20.84 |
Average Payables |
— | — | 0.12 | 2.16 | 11.96 | 16.17 | 16.17 | 24.70 | 46.79 | 69.44 |
Average Inventory |
— | — | — | — | 2.56 | 1.97 | 1.97 | 2.80 | 3.33 | 3.61 |
Average Assets |
— | 0.10 | 0.20 | 39.07 | 39.07 | 82.23 | 82.23 | 93.92 | 97.13 | 228.97 |
Average Common Equity |
— | 0.02 | 0.02 | (111.93) | (111.93) | (93.82) | (93.82) | (68.35) | (182.79) | (202.20) |
Columns are period end dates